Vaccine candidate against COVID-19

iNCOVACC    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

iNCOVACC: Vaccine candidate against COVID-19
iNCOVACC is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, American company Precision Virologics and the Washington University School of Medicine in St Louis, Missouri, United States.


You Might Like

Covid-19: Health Minister launches Bharat Biotech's first India-made nasal vaccine, all you need to know

The first nasal Covid-19 vaccine developed in India by Bharat Biotech, iNCOVACC launches on the 74th Republic Day.
DNA - Published

Centre launches Bharat Biotech's iNCOVACC, India's first nasal Covid vaccine

On the occasion of Republic Day, India got its first-ever intranasal vaccine iNCOVACC, which will be manufactured by Hyderabad-based Bharat Biotech.The vaccine, dubbed "game changer" by some experts,..
IndiaTimes - Published

India gets first nasal Covid vaccine: How it can be the 'game changer'

Centre on Thursday launched India's first nasal Covid-19 vaccine iNCOVACC. Bharat Biotech's Incovacc received government approval for use as a booster dose in the country-wide mass inouclation program...
IndiaTimes - Published

Covid-19: Bharat Biotech's iNCOVACC nasal vaccine to hit markets from February; know prices, eligibility

Bharat Biotech's iNCOVACC will be the country of India's first needleless booster shot which will be available in private hospitals.
DNA - Published

First nasal vaccine for Covid-19, Bharat Biotech's iNCOVACC, to be launched on January 26

Bharat Biotech will offer the intranasal vaccine for Rs 325 to the government and Rs 800 to private hospitals.
DNA - Published

First Indian intranasal Covid vaccine to be launched on January 26

Homegrown vaccine maker Bharat Biotech will launch its intranasal Covid-19 vaccine iNCOVACC, the first of its kind in India, on January 26, the company's chairman and managing director Krishna Ella..
IndiaTimes - Published

Bharat Biotech's nasal vaccine at Rs 800 for private centres and Rs 325 for govt hospitals

Bharat Biotech’s intranasal Covid-19 vaccine iNCOVACC will be priced at Rs 800 per dose in private markets and at Rs 325 per dose for procurement by central and state governments, the vaccine maker..
IndiaTimes - Published

Bharat Biotech's nasal vaccine to be priced at Rs 800/dose in pvt markets, Rs 325/dose for governments

Bharat Biotech on Tuesday said that its intranasal Covid-19 vaccine iNCOVACC will be priced at Rs 800 per dose for the private markets and Rs 325 per dose for central and state governments. The company..
IndiaTimes - Published

CDSCO grants EUA to Bharat Bio's intranasal Covid-19 vaccine

The Central Drugs Standard Control Organisation (CDSCO) has granted approval to BBV154 for restricted use in emergency situation, Union health minister Dr Mansukh Mandaviya announced via a tweet on..
IndiaTimes - Published

Bharat Biotech submits intranasal vaccine data to drug regulator, says vax safe and immunogenic

Bharat Biotech International Limited (BBIL) on Monday said its intranasal Covid-19 vaccine BBV154 has proved to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials for..
IndiaTimes - Published